Asia-Pacific Cancer Biomarker Market

Asia-Pacific Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker, and Protein Biomarker), by Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Other), by Applications (Drug Discovery and Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period 2019-2025
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2020995 | Category : Biotechnology | Delivery Format: /

Asia-Pacific cancer biomarkers market is growing at a CAGR of around 11.9% during the forecast period. APAC is both a strong and promising market for biomarkers. This is particularly due to the strong population base, high prevalence of cancer in Asian countries such as China, Japan. Half of the global incidence of cancer is projected to occur in Asia with 22% in China and 7% in India alone. Biomarker development and adoption in these Asian countries will reduce the economic burden of cancer on the respective governments by timely and efficient diagnosis of diseases. 

Visit for Global Cancer Biomarker Market Report at: https://www.omrglobal.com/industry-reports/cancer-biomarkers-market

Changing lifestyles, increasing urbanization, changes in reproductive patterns and diet, obesity, tobacco use, alcohol drinking, chronic infection and increasing lifespans contribute to an ever-increasing cancer burden and changing cancer pattern in Asian countries. The projected increase will be largest in low-resource and medium-resource countries in Asia. The cancer biomarker market has huge opportunities in APAC due to increase in cancer cases, increase in R&D and growing medical tourism. China is the second largest economy after the US and China has the world’s largest population (1.4 billion), followed by India (1.3 billion). Both China and India hold 40% of total world population share. As population of India and China grows, its expanding share of older adults is particularly notable.

The United Nations Population Division projects that in India’s population with age 50 years and older will reach 34% by 2050. Between 2010 and 2050, the share of 65 and older is expected to increase from 5% to 14%, while the share in the oldest age group (80 and older) will triple from 1% to 3%. Furthermore, Chinese authorities are projecting the country's aged population (above 60 years old) will reach 255 million by 2020. The country’s ageing population will grow at an average rate of 6.4 million a year. By 2020, there will be 255 million elders, representing at least 17.8% of the entire Chinese population. With the age dynamics, cancer cases in Asia Pacific are expected to grow.

Research Methodology

The market study of the Asia-Pacific cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Asia-Pacific Cancer Biomarker Market Research and Analysis by Biomarker Type

2. Asia-Pacific Cancer Biomarker Market Research and Analysis by Cancer Type

3. Asia-Pacific Cancer Biomarker Market Research and Analysis by Application

4. Asia-Pacific Cancer Biomarker Market Research and Analysis by Profiling Technology

The Report Covers

  • Comprehensive research methodology of the Asia-Pacific Cancer biomarker market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific Cancer biomarker market.
  • Insights about market determinants which are stimulating the Asia-Pacific Cancer biomarker market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis 

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants 

4.1. Motivators

4.2. Restraints

4.3. Opportunities 

5. Market Segmentation

5.1. Asia-Pacific Cancer Biomarker Market by Biomarker Type

5.1.1. Genetic Biomarker

5.1.2. Protein Biomarker

5.2. Asia-Pacific Cancer Biomarkers Market by Cancer Type

5.2.1. Lung Cancer

5.2.2. Prostate Cancer

5.2.3. Breast Cancer

5.2.4. Colorectal Cancer

5.2.5. Cervical Cancer

5.2.6. Other

5.3. Asia-Pacific Cancer Biomarkers Market by Applications

5.3.1. Drug Discovery and Development

5.3.2. Diagnosis

5.3.3. Risk Assessment

5.3.4. Prognostics

5.4. Asia-Pacific Cancer Biomarker Market by Profiling Technology

5.4.1. Omics Technology

5.4.2. Immunoassays

5.4.3. Cytogenetics

5.4.4. Bioinformatics

6. Regional Analysis

6.1. China

6.2. India

6.3. Japan

6.4. Rest of Asia-Pacific

7. Company Profiles

7.1. Abbott laboratories Inc.

7.2. Astellas Pharma Inc.

7.3. Becton, Dickson and Co.

7.4. Bio-Rad Laboratories, Inc.

7.5. Danaher Corp.

7.6. F. Hoffmann-La Roche Ltd.

7.7. Merck and Co., Inc.

7.8. Novartis AG

7.9. Pfizer Inc.

7.10.  QIAGEN GmbH

7.11.  Thermo Fisher Scientific Inc.

1. ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2018-2025 ($ MILLION)

2. ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)

3. ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)

4. ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY PROFILING TECHNOLOGY, 2018-2025 ($ MILLION) 

5. ASIA-PACIFIC CANCER BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)


1. ASIA-PACIFIC CANCER BIOMARKER MARKET SHARE BY BIOMARKER TYPE, 2018 VS 2025 (%)

2. ASIA-PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)

3. ASIA-PACIFIC CANCER BIOMARKER MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)

4. ASIA-PACIFIC CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY, 2018 VS 2025 (%)

5. ASIA-PACIFIC CANCER BIOMARKER MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)

6. CHINA CANCER BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)

7. INDIA CANCER BIOMARKER MARKET SIZE, 2018-2025 ($ MILLION)